東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Drug Resistance in Mycobacterium tub...

Abanda, Ngu Njei.

Linked to FindBook

Google Book

Amazon

博客來

Drug Resistance in Mycobacterium tuberculosis: An Investigation of Drug Transporter P-Glycoprotein and an Evaluation of Improved Diagnosis of Drug Resistant Tuberculosis in Cameroonian Pulmonary Tuberculosis Patients.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Drug Resistance in Mycobacterium tuberculosis: An Investigation of Drug Transporter P-Glycoprotein and an Evaluation of Improved Diagnosis of Drug Resistant Tuberculosis in Cameroonian Pulmonary Tuberculosis Patients./
Author:	Abanda, Ngu Njei.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2017,
Description:	168 p.
Notes:	Source: Dissertations Abstracts International, Volume: 79-04, Section: B.
Contained By:	Dissertations Abstracts International79-04B.
Subject:	Microbiology. -
Online resource:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10656545
ISBN:	9780355264272

Drug Resistance in Mycobacterium tuberculosis: An Investigation of Drug Transporter P-Glycoprotein and an Evaluation of Improved Diagnosis of Drug Resistant Tuberculosis in Cameroonian Pulmonary Tuberculosis Patients.
Abanda, Ngu Njei.

Drug Resistance in Mycobacterium tuberculosis: An Investigation of Drug Transporter P-Glycoprotein and an Evaluation of Improved Diagnosis of Drug Resistant Tuberculosis in Cameroonian Pulmonary Tuberculosis Patients. - Ann Arbor : ProQuest Dissertations & Theses, 2017 - 168 p.

Source: Dissertations Abstracts International, Volume: 79-04, Section: B.

Thesis (Ph.D.)--University of Hawai'i at Manoa, 2017.

This item must not be sold to any third party vendors.

Tuberculosis (TB) is a major health problem, especially in Africa and Southeast Asia. The disease, caused by Mycobacterium tuberculosis , (Mtb) is curable with a multidrug regimen of Rifampicin (RIF), Isoniazid (INH), Ethambutol and Pyrazinamide. However, treatment is not always successful, as ~ 2 million patients fail treatment each year, in part, because the bacterium has become resistant to these drugs. Thus, efficient diagnosis of drug-resistant Mtb is extremely important. This study sought to determine if a new molecular assay, the Genotype MTBDR plus, could accurately detect drugresistant Mtb in Cameroon. When compared to the conventional drug susceptibility testing assay, the molecular assay identified 98% (48/49) RIF-resistant isolates, 92% (55/60) INH-resistant isolates, and 94% (46/49) of Mtb resistant to both drugs in Cameroonian TB patients. Further evaluation of the molecular assay with an additional 50 Mtb isolates , identified 6% (16/275) of isolates with questionable RIF-resistant results. To determine if these 16 isolates were truly RIF-resistant, the Rifampicin Resistance-determining Region of the rpoB gene were sequenced. Mutations were found known as 'disputed' RIF mutations, i.e., mutations that are not always associated with resistance to RIF. Thus, sequencing results confirm that when DNA from Mtb isolates do not hybridize with the wild-type rpoB probe, it is wise to assume the Mtb isolate is RIF-resistant and treat accordingly. The Genotype MTBDRplus assay can be adopted by the government of Cameroon to diagnose drug-resistant TB. In addition to mycobacterial mutations, host factors that cause sub-therapeutic plasma drug concentration could lead to treatment failure. One of such host factors could be variation in the liver efflux pump, P-glycoprotein (p-gp). Therefore, the relative amount of p-gp protein in 87 human liver samples was measured. P-gp was found to be present from birth reaching 90 % of adult levels by age 5. Since low variability (2.9 ± 0.32 fold) in pgp occurred among individuals, it is unlikely variability in p-gp protein accounts for wide variation in RIF plasma levels. The data are important because expression p-gp in children provides a plausible explanation as to why, when given the same dose/kg of RIF as adults, children clear the drug faster.

ISBN: 9780355264272Subjects--Topical Terms:

536250
Microbiology.
Subjects--Index Terms:

Cameroon

Drug Resistance in Mycobacterium tuberculosis: An Investigation of Drug Transporter P-Glycoprotein and an Evaluation of Improved Diagnosis of Drug Resistant Tuberculosis in Cameroonian Pulmonary Tuberculosis Patients.
LDR:03717nmm a2200397 4500 001 2281330
005 20210920102938.5
008 220723s2017 ||||||||||||||||| ||eng d
020 $a 9780355264272
035 $a (MiAaPQ)AAI10656545
035 $a AAI10656545
040 $a MiAaPQ $c MiAaPQ
100 1 $a Abanda, Ngu Njei. $3 3559912
245 1 0 $a Drug Resistance in Mycobacterium tuberculosis: An Investigation of Drug Transporter P-Glycoprotein and an Evaluation of Improved Diagnosis of Drug Resistant Tuberculosis in Cameroonian Pulmonary Tuberculosis Patients.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2017
300 $a 168 p.
500 $a Source: Dissertations Abstracts International, Volume: 79-04, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Wallace Taylor, Diane.
502 $a Thesis (Ph.D.)--University of Hawai'i at Manoa, 2017.
506 $a This item must not be sold to any third party vendors.
520 $a Tuberculosis (TB) is a major health problem, especially in Africa and Southeast Asia. The disease, caused by Mycobacterium tuberculosis , (Mtb) is curable with a multidrug regimen of Rifampicin (RIF), Isoniazid (INH), Ethambutol and Pyrazinamide. However, treatment is not always successful, as ~ 2 million patients fail treatment each year, in part, because the bacterium has become resistant to these drugs. Thus, efficient diagnosis of drug-resistant Mtb is extremely important. This study sought to determine if a new molecular assay, the Genotype MTBDR plus, could accurately detect drugresistant Mtb in Cameroon. When compared to the conventional drug susceptibility testing assay, the molecular assay identified 98% (48/49) RIF-resistant isolates, 92% (55/60) INH-resistant isolates, and 94% (46/49) of Mtb resistant to both drugs in Cameroonian TB patients. Further evaluation of the molecular assay with an additional 50 Mtb isolates , identified 6% (16/275) of isolates with questionable RIF-resistant results. To determine if these 16 isolates were truly RIF-resistant, the Rifampicin Resistance-determining Region of the rpoB gene were sequenced. Mutations were found known as 'disputed' RIF mutations, i.e., mutations that are not always associated with resistance to RIF. Thus, sequencing results confirm that when DNA from Mtb isolates do not hybridize with the wild-type rpoB probe, it is wise to assume the Mtb isolate is RIF-resistant and treat accordingly. The Genotype MTBDRplus assay can be adopted by the government of Cameroon to diagnose drug-resistant TB. In addition to mycobacterial mutations, host factors that cause sub-therapeutic plasma drug concentration could lead to treatment failure. One of such host factors could be variation in the liver efflux pump, P-glycoprotein (p-gp). Therefore, the relative amount of p-gp protein in 87 human liver samples was measured. P-gp was found to be present from birth reaching 90 % of adult levels by age 5. Since low variability (2.9 ± 0.32 fold) in pgp occurred among individuals, it is unlikely variability in p-gp protein accounts for wide variation in RIF plasma levels. The data are important because expression p-gp in children provides a plausible explanation as to why, when given the same dose/kg of RIF as adults, children clear the drug faster.
590 $a School code: 0085.
650 4 $a Microbiology. $3 536250
650 4 $a Pharmacology. $3 634543
650 4 $a Public health. $3 534748
653 $a Cameroon
653 $a Drug-resistant tuberculosis
653 $a Genotypic
653 $a MTBDRplus
653 $a Polyprotein
653 $a Tuberculosis
690 $a 0410
690 $a 0419
690 $a 0573
710 2 $a University of Hawai'i at Manoa. $b Biomedical Sciences (Tropical Medicine). $3 3559913
773 0 $t Dissertations Abstracts International $g 79-04B.
790 $a 0085
791 $a Ph.D.
792 $a 2017
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10656545